SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-23-021103
Filing Date
2023-03-17
Accepted
2023-03-17 17:25:34
Documents
70
Period of Report
2023-01-31

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea174997-6k_clearmind.htm   iXBRL 6-K 13588
2 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED J ea174997ex99-1_clearmind.htm   iXBRL EX-99.1 448323
3 MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE FOR THE THREE MONTHS ENDED JANUARY ea174997ex99-2_clearmind.htm EX-99.2 167151
  Complete submission text file 0001213900-23-021103.txt   3718455

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cmnd-20230131.xsd EX-101.SCH 83795
5 XBRL CALCULATION FILE cmnd-20230131_cal.xml EX-101.CAL 27884
6 XBRL DEFINITION FILE cmnd-20230131_def.xml EX-101.DEF 200772
7 XBRL LABEL FILE cmnd-20230131_lab.xml EX-101.LAB 424923
8 XBRL PRESENTATION FILE cmnd-20230131_pre.xml EX-101.PRE 212840
64 EXTRACTED XBRL INSTANCE DOCUMENT ea174997-6k_clearmind_htm.xml XML 436189
Mailing Address 101-1220 WEST 6TH AVENUE VANCOUVER, BRITISH COLUMBIA Z4 V6H1A5
Business Address 101-1220 WEST 6TH AVENUE VANCOUVER, BRITISH COLUMBIA Z4 V6H1A5 972-54-5704749
Clearmind Medicine Inc. (Filer) CIK: 0001892500 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 6-K | Act: 34 | File No.: 001-41557 | Film No.: 23743947
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences